Open AccessCOVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants—A Scoping Review
Author(s) -
Udo Bonnet,
Georg Juckel
Publication year - 2022
Publication title -
journal of clinical psychopharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.786
H-Index - 121
eISSN - 1533-712X
pISSN - 0271-0749
DOI - 10.1097/jcp.0000000000001543
Subject(s) - fluvoxamine , trazodone , fluoxetine , medicine , tolerability , serotonin reuptake inhibitor , reuptake inhibitor , placebo , antidepressant , randomized controlled trial , psychiatry , pharmacology , adverse effect , serotonin , alternative medicine , receptor , pathology , hippocampus
Studies for repurposed drugs in severe acute respiratory syndrome coronavirus type 2-infected and coronavirus disease 2019 (COVID-19) patients are ongoing. According to preclinical research, antidepressants (ADs) might be useful in the treatment of COVID-19.